Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus platinum-based chemotherapy as neoadjuvant therapy for cervical cancer
ChiCTR2500111833Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in Cervical Cancer (CC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Pathological complete response (pCR). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500111833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111833.